Phase II study of enlonstobart (SG001), a novel PD-1 inhibitor in patients with PD-L1 positive recurrent/metastatic cervical cancer.
Li G, Li X, Yin R, Feng M, Zuo J, Wei S, Kang S, Sun H, Li X, Wang Y, Zhang Y, Sun L, Lin D, Ruan X, Zhu Z, Jiang K, Liu H, Wang W, Hao D, Chen Y, Xiang S, Niu M, Wu L.
Li G, et al. Among authors: xiang s.
Gynecol Oncol. 2024 Dec;191:165-171. doi: 10.1016/j.ygyno.2024.10.001. Epub 2024 Oct 23.
Gynecol Oncol. 2024.
PMID: 39447517
Free article.
Clinical Trial.